Abstract
Objective. There are limited data on the reproductive health of women with vasculitis. This study used a prospective, international vasculitis pregnancy registry to survey women during and after pregnancy. Methods. The Vasculitis Pregnancy Registry (VPREG) is imbedded within the Vasculitis Patient-Powered Research Network, an international online research infrastructure. Any pregnant woman with a diagnosis of vasculitis can self-enroll. After enrollment, women are invited to complete online surveys at study entry, once per trimester, and postpartum. Descriptive statistics are reported here. Results. Between 2015 and 2022, 147 women with 149 pregnancies enrolled in VPREG from 16 countries. Data on 78 pregnancies with known outcomes were included in this analysis. During pregnancy, women on average experienced low levels of pain related to vasculitis (scale 0-10, median 2 [IQR 1-5]) and preserved feelings of wellness (scale 0-10, median 3 [IQR 1-5]). Thirty-six percent of women reported their vasculitis was active during pregnancy. Of the 14 women requiring hospitalization during pregnancy outside of delivery, 4 cited active vasculitis as the indication. Most women (54/73, 74%) were prescribed medications for vasculitis during pregnancy. Seventy-six (97%) pregnancies resulted in live births, with 64% delivering vaginally and 21% experiencing a preterm delivery. Conclusion. These results demonstrate that most women with vasculitis can experience pregnancies that result in live births delivered at term. During pregnancy, a minority of women reported flares of vasculitis or the need for hospitalization due to vasculitis. These data are useful to rheumatologists and patients to inform and facilitate discussions about reproductive health and vasculitis.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Journal of Rheumatology |
| Jahrgang | 51 |
| Ausgabenummer | 10 |
| Seiten (von - bis) | 1003-1008 |
| Seitenumfang | 6 |
| ISSN | 0315-162X |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.10.2024 |
Fördermittel
The Vasculitis Patient-Powered Research Network is supported in part by the Vasculitis Foundation and GSK. 1C.A. Sims, MD, Durham Veterans Affairs Healthcare System, Division of Rheumatology & Immunology, Duke University, Durham, North Carolina; 2A.M. Eudy, PhD, Department of Medicine, Duke University, Durham, North Carolina; 3K. Larson, MA, J. Kullman, Vasculitis Foundation, Kansas City, Missouri; 4C. Yeung, BS, Vasculitis Patient-Powered Research Network, University of Pennsylvania, Division of Rheumatology, Philadelphia, Pennsylvania; 5H. Tam, Patient Advocate, Vasculitis Patient-Powered Research Network, University of Pennsylvania, Division of Rheumatology, Philadelphia, Pennsylvania; 6R.L. Borchin, BSW, C. Burroughs, BS, Health Informatics Institute, University of South Florida, Tampa, Florida; 7P.A. Merkel, MD, MPH, Division of Rheumatology, Department of Medicine, and Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania; 8M.E.B. Clowse, MD, MPH, Division of Rheumatology & Immunology, Duke University, Durham, North Carolina, USA. CAS has received grant/research support from UCB. AME has received consultant fees from Amgen; and grant/research support from Exagen, GSK, Immunovant, and Pfizer. PAM has received grant/research support from AbbVie/Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Eicos, Electra, Genentech, GSK, InflaRx, Neutrolis, and Takeda; consultant fees from Amgen, ArGenx, AstraZeneca, Boehringer Ingelheim, BMS, Cabaletta, CSL Behring, GSK, HiBio, InflaRx, Janssen, Jubilant, Kyverna, MiroBio, Novartis, NS Pharma, Q32, Regeneron, Sanofi, Sparrow, Takeda, and Visterra; royalties from UpToDate; and stock options or bond holdings from Kyverna. MEBC has received grant/research support from Exagen, GSK, and Immunovant; and consultant fees from UCB and GSK. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. C.A. Sims, MD, Health Service Research Fellow, Durham Veterans Affairs Healthcare System, Division of Rheumatology & Immunology, Duke University, 40 Duke Medicine Circle Clinic 1J, Durham, NC 27713, USA. Email: [email protected]. Accepted for publication May 15, 2024.
| Träger | Trägernummer |
|---|---|
| GlaxoSmithKline | |
| Cerebrovascular and Vasculitis Research Foundation | |
| Pfizer | |
| School of Public Health, University of California Berkeley |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
DFG-Fachsystematik
- 2.21-05 Immunologie
- 2.22-18 Rheumatologie
Fingerprint
Untersuchen Sie die Forschungsthemen von „Reproductive Outcomes for Women With Vasculitis“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver